摘要
目的：评价重组人白介素-11（Ⅰ）[rhIL-11（Ⅰ）]和重组人促血小板生成素（rhTPO）治疗吉西他滨联合化疗相关血小板减少的效果和经济学意义。方法：采用回顾性分析法,收集2011年6月~2014年6月接受吉西他滨化疗导致血小板减少而使用rhIL-11（Ⅰ）或rhTPO治疗的58例肺癌住院患者,比较两种升血小板药物的疗效,并做经济学评价。结果：rhIL-11（Ⅰ）组患者化疗后血小板最低值高于rh TPO组（P〈0.01）;治疗后血小板持续减少时间短于rhTPO组（P〈0.01）。但两组血小板达标比例差异无统计学意义（P〉0.05）。采用最小成本分析,rhIL-11（Ⅰ）组平均成本低于rhTPO组（P〈0.01）,rhIL-11（Ⅰ）组中不论接受GP、GC或其他以吉西他滨为基础的化疗方案,患者的平均成本均低于rhTPO组。结论：rh IL-11（Ⅰ）用于以吉西他滨为基础联合化疗治疗的肺癌患者后引起的血小板减少效果不劣于rhTPO,且在经济成本上具有一定优势。
Objective： To evaluate the efficacy and pharmacoeconomics of rhIL-11（ Ⅰ） and rh TPO in the treatment of thrombocytopenia caused by gemcitabine chemotherapy in lung cancer patients. Methods： A retrospective analysis was used. Totally 58 hospitalized lung cancer patients who suffered thrombocytopenia caused by gemcitabine chemotherapy and treated with rhIL-11（ Ⅰ） or rh TPO from June 2011 to June 2014 were involved in the study,and the efficacy and pharmacoeconomics of rhIL-11（ Ⅰ） and rh TPO were evaluated and compared. Results： The lowest platelet value after the chemotherapy in rhIL-11（ Ⅰ） group was higher than that in rh TPO group（ P 0. 01）,and the platelet decrease time in rhIL-11（ Ⅰ） group was shorter than that in rhTPO group（ P 0. 01）,while the platelet qualified rate of the two groups showed no statistically significant difference（ P 0. 05）. The results of cost-minimization analysis showed that the average cost of rhIL-11（ Ⅰ） group was lower than that of rh TPO group（ P 0. 01）,furthermore,the average cost of the patients with GP,GC or the other gemcitabine chemotherapy regimens in rhIL-11（ Ⅰ） group was lower than that in rhTPO group. Conclusion： The effect of rhIL-11（ Ⅰ） in the treatment of thrombocytopenia caused by gemcitabine based-chemotherapy in lung cancer patients is not inferior to that of rhTPO,and shows certain advantages in economic cost.
出处
《中国药师》
CAS
2015年第2期250-252,共3页
China Pharmacist
基金
浙江省卫生高层次创新人才培养工程(编号:2010-190-4)
